125 related articles for article (PubMed ID: 35655425)
1. Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.
Takeshima M; Enomoto M; Ogasawara M; Kudo M; Itoh Y; Yoshizawa K; Fujiwara D; Takaesu Y; Mishima K
Psychiatry Clin Neurosci; 2022 Sep; 76(9):475-477. PubMed ID: 35655425
[No Abstract] [Full Text] [Related]
2. Changes in Prescription of Psychotropic Drugs After Introduction of Polypharmacy Reduction Policy in Japan Based on a Large-Scale Claims Database.
Hirano Y; Ii Y
Clin Drug Investig; 2019 Nov; 39(11):1077-1092. PubMed ID: 31399894
[TBL] [Abstract][Full Text] [Related]
3. Prescribing Trends Psychotropic Drugs Against Children and Adolescents and Association with Polypharmacy Reduction Policy for Psychotropic Drugs: Based on Japanese National Database Survey.
Park J; Okui T; Nakashima N
Stud Health Technol Inform; 2022 Jun; 290():1132-1133. PubMed ID: 35673241
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the trends of polypharmacy and high-dose prescriptions in Japan.
Shinfuku N
Asia Pac Psychiatry; 2022 Mar; 14(1):e12488. PubMed ID: 34519433
[TBL] [Abstract][Full Text] [Related]
5. Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy: A Study Based on Large-Scale Japanese Claims Data.
Hirano Y
Ther Innov Regul Sci; 2020 Mar; 54(2):259-268. PubMed ID: 31933179
[TBL] [Abstract][Full Text] [Related]
6. Nationwide Long-Term Evaluation of Polypharmacy Reduction Policies Focusing on Older Adults in Japan.
Ishida T; Suzuki A; Nakata Y
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429409
[TBL] [Abstract][Full Text] [Related]
7. [Merits and Demerits of High-dose Psychotropic Polypharmacy in Schizophrenia from Guidelines].
Hashimoto R; Yasuda Y; Fujimoto M; Yamamori H
Seishin Shinkeigaku Zasshi; 2017; 119(3):185-191. PubMed ID: 30620854
[TBL] [Abstract][Full Text] [Related]
8. Effects of medical service fee revision on reducing irrational psychotropic polypharmacy in Japan: an interrupted time-series analysis.
Okada Y; Akazawa M
Soc Psychiatry Psychiatr Epidemiol; 2022 Feb; 57(2):411-422. PubMed ID: 34333670
[TBL] [Abstract][Full Text] [Related]
9. Prevention of overlapping prescriptions of psychotropic drugs by community pharmacists.
Shimane T; Matsumoto T; Wada K
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2012 Oct; 47(5):202-10. PubMed ID: 23393998
[TBL] [Abstract][Full Text] [Related]
10. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics.
Yang SY; Chen LY; Najoan E; Kallivayalil RA; Viboonma K; Jamaluddin R; Javed A; Hoa DTQ; Iida H; Sim K; Swe T; He YL; Park Y; Ahmed HU; De Alwis A; Chiu HF; Sartorius N; Tan CH; Chong MY; Shinfuku N; Lin SK
Psychiatry Clin Neurosci; 2018 Aug; 72(8):572-579. PubMed ID: 29761577
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors.
Nørgaard A; Jensen-Dahm C; Gasse C; Hansen ES; Waldemar G
J Alzheimers Dis; 2017; 56(2):707-716. PubMed ID: 28035931
[TBL] [Abstract][Full Text] [Related]
12. Psychotropic polypharmacy for the treatment of bipolar disorder in Taiwan.
Hung GC; Yang SY; Chen Y; Lin SK
Psychiatr Serv; 2014 Jan; 65(1):125-8. PubMed ID: 24382766
[TBL] [Abstract][Full Text] [Related]
13. The definition and prevalence of pediatric psychotropic polypharmacy.
Chen H; Patel A; Sherer J; Aparasu R
Psychiatr Serv; 2011 Dec; 62(12):1450-5. PubMed ID: 22193792
[TBL] [Abstract][Full Text] [Related]
14. Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008.
Fontanella CA; Warner LA; Phillips GS; Bridge JA; Campo JV
Psychiatr Serv; 2014 Nov; 65(11):1332-40. PubMed ID: 25022817
[TBL] [Abstract][Full Text] [Related]
15. Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia.
Huang CY; Yang SY; Mojtabai R; Lin SK; He YL; Chong MY; Ungvari G; Tan CH; Xiang YT; Sartorius N; Shinfuku N; Chen LY
J Clin Psychopharmacol; 2018 Dec; 38(6):598-603. PubMed ID: 30273199
[TBL] [Abstract][Full Text] [Related]
16. Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability.
Espadas C; Ballester P; Londoño AC; Almenara S; Aguilar V; Belda C; Pérez E; Peiró AM
Psychiatry Res; 2020 Oct; 292():113321. PubMed ID: 32738553
[TBL] [Abstract][Full Text] [Related]
17. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study.
Kochi K; Sato I; Nishiyama C; Tanaka-Mizuno S; Doi Y; Arai M; Fujii Y; Matsunaga T; Ogawa Y; Furukawa TA; Kawakami K
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):642-656. PubMed ID: 28266090
[TBL] [Abstract][Full Text] [Related]
18. Gender differences and psychotropic polypharmacy in psychiatric patients in Brazil: a cross-sectional analysis of the PESSOAS Project.
Costa JO; Ceccato MDGB; Melo APS; Acurcio FA; Guimarães MDC
Cad Saude Publica; 2017 May; 33(4):e00168915. PubMed ID: 28538794
[TBL] [Abstract][Full Text] [Related]
19. [Psychotropic Prescribing Practices for Children and Adolescents with Intellectual Disabilities: A Cohort Study Using a Large-scale Health Insurance Database].
Inoue Y; Okumura Y; Fujita J
Seishin Shinkeigaku Zasshi; 2016; 118(11):823-833. PubMed ID: 30620838
[TBL] [Abstract][Full Text] [Related]
20. Psychotropic drugs prescription at two regional psychiatric hospitals in northern Nigeria.
Adeponle AB; Obembe AO; Nnaji F; Adeyemi SO; Suleiman GT
West Afr J Med; 2008 Apr; 27(2):106-10. PubMed ID: 19025025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
